Maxcyte Stock Investor Sentiment

MXCT Stock  USD 3.55  0.03  0.85%   
Slightly above 65% of MaxCyte's investor base is looking to short. The analysis of overall sentiment of trading MaxCyte stock suggests that many investors are alarmed at this time. MaxCyte's investing sentiment can be driven by a variety of factors including economic data, MaxCyte's earnings reports, geopolitical events, and overall market trends.
  

MaxCyte Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards MaxCyte can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a week ago at finance.yahoo.com         
This MaxCyte Insider Increased Their Holding In The Last Year
Yahoo News
over a week ago at news.google.com         
MaxCyte stock touches 52-week low at 3.23 amid market challenges - Investing.com
Google News at Macroaxis
over two weeks ago at news.google.com         
Will MaxCytes Q2 Results Surpass Market Expectations - RTTNews
Google News at Macroaxis
over two weeks ago at gurufocus.com         
CADIAN CAPITAL MANAGEMENT, LP Expands Stake in MaxCyte Inc
Gurufocus Stories at Macroaxis
over two weeks ago at globenewswire.com         
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
Macroaxis News: globenewswire.com
over three weeks ago at www.macroaxis.com         
Disposition of 47689 shares by Erck Stanley C of MaxCyte at 3.72 subject to Rule 16b-3
Macroaxis News
over three weeks ago at simplywall.st         
MaxCyte Third Quarter 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over three weeks ago at insidermonkey.com         
MaxCyte, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at gurufocus.com         
MaxCyte Inc Q3 2024 Earnings Call Highlights Strong Core Revenue Growth Amidst Market ...
Gurufocus Stories at Macroaxis
over three weeks ago at simplywall.st         
Investors ignore increasing losses at MaxCyte as stock jumps 10 percent this past week
Simply Wall St News at Macroaxis
over three weeks ago at gurufocus.com         
Q3 2024 MaxCyte Inc Earnings Call Transcript
Gurufocus Stories at Macroaxis
over three weeks ago at finance.yahoo.com         
MaxCyte Inc Q3 2024 Earnings Call Highlights Strong Core Revenue Growth Amidst Market ...
Yahoo News
over three weeks ago at finance.yahoo.com         
MaxCyte, Inc. Reports Q3 Loss, Tops Revenue Estimates
Yahoo News
over three weeks ago at zacks.com         
MaxCyte, Inc. Reports Q3 Loss, Tops Revenue Estimates
zacks News
over three weeks ago at gurufocus.com         
MaxCyte Inc Q3 2024 Earnings Revenue Surpasses Estimates at 8.2M, EPS of -0. ...
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about MaxCyte that are available to investors today. That information is available publicly through MaxCyte media outlets and privately through word of mouth or via MaxCyte internal channels. However, regardless of the origin, that massive amount of MaxCyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MaxCyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MaxCyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MaxCyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MaxCyte alpha.

MaxCyte Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 25000 shares by Soleymannezhad Ali of MaxCyte at 5.02 subject to Rule 16b-3
09/11/2024
2
Acquisition by Soleymannezhad Ali of 20800 shares of MaxCyte at 4.12 subject to Rule 16b-3
09/16/2024
3
Disposition of 26082 shares by Erck Stanley C of MaxCyte at 0.04 subject to Rule 16b-3
10/01/2024
4
MaxCyte Inc Q2 2024 Earnings Call Highlights Revenue Growth Amid Core Challenges
10/09/2024
5
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
10/11/2024
6
Insider Trading
10/14/2024
7
Acquisition by Swirsky Douglas J of 81250 shares of MaxCyte subject to Rule 16b-3
10/18/2024
8
Disposition of 3000 shares by Johnston John Joseph of MaxCyte at 2.926 subject to Rule 16b-3
10/28/2024
9
MaxCyte director Johnston sells 11,166 in stock
10/30/2024
10
Disposition of 47689 shares by Erck Stanley C of MaxCyte at 0.04 subject to Rule 16b-3
11/01/2024
11
MaxCyte Inc Q3 2024 Earnings Revenue Surpasses Estimates at 8.2M, EPS of -0. ...
11/06/2024
12
Q3 2024 MaxCyte Inc Earnings Call Transcript
11/07/2024
13
MaxCyte Third Quarter 2024 Earnings Beats Expectations
11/08/2024
14
CADIAN CAPITAL MANAGEMENT, LP Expands Stake in MaxCyte Inc
11/14/2024
15
This MaxCyte Insider Increased Their Holding In The Last Year
11/21/2024

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.